These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23562852)

  • 1. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression.
    Poland RE; Lesser IM; Wan YJ; Gertsik L; Yao J; Raffel LJ; Lin KM; Myers HF
    Life Sci; 2013 May; 92(20-21):967-70. PubMed ID: 23562852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
    Manoharan A; Shewade DG; Rajkumar RP; Adithan S
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
    Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
    Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
    Kronenberg S; Apter A; Brent D; Schirman S; Melhem N; Pick N; Gothelf D; Carmel M; Frisch A; Weizman A
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):741-50. PubMed ID: 18315446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.
    Shiroma PR; Drews MS; Geske JR; Mrazek DA
    Am J Geriatr Psychiatry; 2014 Nov; 22(11):1140-8. PubMed ID: 23973251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
    Ng C; Sarris J; Singh A; Bousman C; Byron K; Peh LH; Smith DJ; Tan CH; Schweitzer I
    Hum Psychopharmacol; 2013 Sep; 28(5):516-22. PubMed ID: 24014145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics.
    Nellissery M; Feinn RS; Covault J; Gelernter J; Anton RF; Pettinati H; Moak D; Mueller T; Kranzler HR
    Alcohol Clin Exp Res; 2003 Sep; 27(9):1402-8. PubMed ID: 14506400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
    Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
    Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
    Muhonen LH; Lahti J; Alho H; Lönnqvist J; Haukka J; Saarikoski ST
    Psychiatry Res; 2011 Mar; 186(1):53-7. PubMed ID: 20800901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5-HTTLPR-S/Lg polymorphisms.
    Ramasubbu R; Burgess A; Gaxiola-Valdez I; Cortese F; Clark D; Kemp A; Goodyear B; Macqueen G; Bech-Hansen NT; Foster J; Diwadkar VA
    Hum Psychopharmacol; 2016 Mar; 31(2):144-55. PubMed ID: 26879101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.
    Bousman CA; Sarris J; Won ES; Chang HS; Singh A; Lee HY; Ham BJ; Tan CH; Lee MS; Ng CH
    J Clin Psychopharmacol; 2014 Oct; 34(5):645-8. PubMed ID: 24943391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.
    Lekman M; Laje G; Charney D; Rush AJ; Wilson AF; Sorant AJ; Lipsky R; Wisniewski SR; Manji H; McMahon FJ; Paddock S
    Biol Psychiatry; 2008 Jun; 63(12):1103-10. PubMed ID: 18191112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic variation at the SLC6A4 gene promoter in mother-child pairs with major depressive disorder.
    Mendonça MS; Mangiavacchi PM; De Sousa PF; Crippa JAS; Mendes AV; Loureiro SR; Martín-Santos R; Quirino CR; Kanashiro MM; Rios AFL
    J Affect Disord; 2019 Feb; 245():716-723. PubMed ID: 30447571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population.
    Mandal T; Bairy LK; Sharma PSVN
    Eur J Clin Pharmacol; 2020 Jun; 76(6):807-814. PubMed ID: 32253447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.
    Kraft JB; Peters EJ; Slager SL; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
    Biol Psychiatry; 2007 Mar; 61(6):734-42. PubMed ID: 17123473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.
    Binder EB; Owens MJ; Liu W; Deveau TC; Rush AJ; Trivedi MH; Fava M; Bradley B; Ressler KJ; Nemeroff CB
    Arch Gen Psychiatry; 2010 Apr; 67(4):369-79. PubMed ID: 20368512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
    Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.
    Garriock HA; Tanowitz M; Kraft JB; Dang VC; Peters EJ; Jenkins GD; Reinalda MS; McGrath PJ; von Zastrow M; Slager SL; Hamilton SP
    Am J Psychiatry; 2010 May; 167(5):565-73. PubMed ID: 20194481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.